Article type:
Research
Estimated read time:
2 mins min read
Published:
21/10/2025
A rare childhood disease called STING-associated vasculopathy with onset in infancy (SAVI) causes serious lung problems. A 5-year-old boy in Japan was treated with a medicine called baricitinib, which blocks certain immune signals. After starting the treatment, his breathing, energy, and growth improved, and his lung scans showed healing. This gives hope that such medicines can help children with SAVI live longer and healthier lives.
Why it Matters This case demonstrates that JAK inhibitors can improve both clinical symptoms and radiological lung damage in SAVI, even when disease is advanced. Since early treatment may prevent irreversible lung damage, the findings support the importance of early genetic diagnosis and consideration of JAK inhibitors in children.
Hope for the Future While SAVI remains a life-threatening disease with limited treatment options, JAK inhibitors represent a promising therapy that could improve survival and quality of life. More case reports and studies will be needed to establish long-term safety, best timing for treatment initiation, and whether early intervention can prevent progression to pulmonary fibrosis.
Read more
Background SAVI is a rare genetic autoinflammatory disease caused by type I interferon dysregulation. It leads to systemic inflammation, skin vasculopathy, and severe interstitial lung disease (ILD), which often determines prognosis. Conventional treatments like corticosteroids and immunosuppressants usually fail, and the mortality rate is high in childhood and young adulthood. Recent reports suggest Janus kinase (JAK) inhibitors may offer benefit.
What the Study Found The report describes a 5-year-old Japanese boy with SAVI and severe lung involvement. He was treated with the JAK1/2 inhibitor baricitinib. After treatment, his breathing and energy improved, his oxygen needs decreased, and he gained weight. Laboratory markers (KL-6) declined, and lung CT scans showed marked improvement in previously observed abnormalities (air-trapping, ground-glass opacities, and subpleural lesions).
Citation Sato et al., Pediatr Int. 2025;67:e70148.
Authors Tomomi Sato, Yukihiro Nagatani, Yukiko Hirota, Tomoaki Kunitsu, Yoshihiro Maruo
Date of publication 10/8/25
Link 10.1111/ped.70148